

# Contents

<b>1</b>	<b>Ankylosing Spondylitis as a Scientific Problem</b>	<b>1</b>
1.1	Ankylosing Spondylitis: An Introduction	1
1.2	Clinical Features of Ankylosing Spondylitis	1
1.3	Radiological Features of Ankylosing Spondylitis	2
1.4	The Disability of Ankylosing Spondylitis	3
1.5	The Social and Financial Costs of Ankylosing Spondylitis	3
1.6	Molecular Mimicry and Rheumatic Fever	4
1.7	The Properties of the Ankylosing Spondylitis Problem	4
1.8	King's College Immunology Unit	5
	References	6
<b>2</b>	<b>History of the Origin of Ankylosing Spondylitis</b>	<b>7</b>
2.1	Introduction	7
2.2	Ankylosing Spondylitis and the Egyptian Pharaohs	7
2.3	Ankylosing Spondylitis in the Middle Ages	8
2.4	Ankylosing Spondylitis and Realdo de Colombo	8
2.5	Connor's Observations in France	8
2.6	The Eighteenth Century in Europe	10
2.7	The Nineteenth Century in London	10
2.8	Bechterew in St. Petersburg	10
2.9	Strümpell in Erlangen and Berlin	11
2.10	Pierre Marie and Léri in France	11
2.11	Buckley's Observations in the 1930s	11
2.12	The Heart and Ankylosing Spondylitis	12
2.13	Diagnostic Help from Physics	12
2.14	Conclusion	12
	References	12

<b>3</b>	<b>The Discovery of HLA-B27 in Ankylosing Spondylitis and Related Disorders</b>	15
3.1	The Tissue Typing Unit at the Westminster Hospital	15
3.2	HLA-B27 in Ankylosing Spondylitis	15
3.3	Acute Anterior Uveitis and HLA-B27	16
3.4	HLA-B27 in Reiter's Disease and Reactive Arthritis	16
3.5	HLA-B27 as the Predisposing Gene	17
3.6	Geography of HLA-B27	17
3.7	General Discussion and Conclusions	18
3.8	The Middlesex Hospital in London	18
3.9	The 'Ankylosing Spondylitis Research Clinic of the Middlesex Hospital'	19
	References	20
<b>4</b>	<b>Molecular Mimicry Between HLA-B27 and <i>Klebsiella</i> Bacteria Investigated by Using Rabbit Antisera</b>	23
4.1	Introduction: The Problem of HLA-B27 in Ankylosing Spondylitis	23
4.2	Rabbit Immunisations	23
4.3	Immunodiffusion Experiments	24
4.4	Haemagglutination Method	25
4.5	Bacterial Agglutination	25
4.6	Radio-Binding Assay with <i>Klebsiella</i> Sonicate Preparation (KSP)	26
4.7	Lymphocytotoxicity Assay	26
4.8	Results of Immunodiffusion Experiments	27
4.9	Haemagglutination Results	28
4.10	Bacterial Agglutination Results	29
4.11	Results of Radio-Binding Assay with <i>Klebsiella</i> Sonicate Preparation (KSP)	29
4.12	Cytotoxicity Results	30
4.13	Discussion and Conclusions	31
	References	32
<b>5</b>	<b>Molecular Mimicry Between HLA-B27 and <i>Klebsiella</i> Bacteria Investigated by Using Human Tissue Typing Sera</b>	35
5.1	Introduction: Molecular Mimicry and Tissue Typing Sera	35
5.2	Bristol	36
5.3	HLA Tissue Typing Sera	36
5.4	Haemagglutination Method	36
5.5	Labelling of <i>Klebsiella</i> Sonicate Preparation (KSP)	36
5.6	Radio-Binding Assay for <sup>125</sup> I- <i>Klebsiella</i> Sonicate Preparation	37
5.7	Competition Assay for <sup>125</sup> I- <i>Klebsiella</i> Sonicate Preparation	37
5.8	Results of Haemagglutination Studies with HLA Typing Sera	38
5.9	Results of Radio-Binding Assay for <sup>125</sup> I- <i>Klebsiella</i> Sonicate Preparation by HLA Typing Sera	38

5.10	Results of Competition Binding Assays .....	40
5.11	Discussion and Conclusions .....	40
	References .....	43
<b>6</b>	<b>Muscle Changes in Ankylosing Spondylitis .....</b>	<b>45</b>
6.1	Introduction: Involvement of Muscle Pathology in Ankylosing Spondylitis .....	45
6.2	Muscle Stiffness, Muscle Pain and the Enthesis .....	45
6.3	Patients and Controls .....	46
6.4	Blood Samples, Muscle Biopsies and Histology .....	46
6.5	Muscle Strength and Electromyographic Studies .....	47
6.6	Results of Histological and Biochemical Investigations .....	47
6.7	Muscle Strength Measurements and Surface Electromyography .....	48
6.8	Pathological and Clinical Implications. ....	49
	References .....	50
<b>7</b>	<b>Raised Serum IgA Is Present in Ankylosing Spondylitis Patients .....</b>	<b>51</b>
7.1	Introduction: Immunoglobulin Levels and Disease Activity in Ankylosing Spondylitis .....	51
7.2	Ankylosing Spondylitis Patients and Controls .....	52
7.3	Methods Used in Estimating Serum Immunoglobulins .....	52
7.4	Results of Serum IgA Estimations .....	52
7.5	Results of Serum IgG Estimations .....	53
7.6	Results of Serum IgM Estimations. ....	56
7.7	Discussion .....	57
7.8	Pathological and Clinical Implications .....	58
	References .....	58
<b>8</b>	<b>Faecal Cultures in Ankylosing Spondylitis and Uveitis .....</b>	<b>61</b>
8.1	Introduction: The Origin of Ankylosing Spondylitis .....	61
8.2	Ankylosing Spondylitis Patients and Controls .....	62
	8.2.1 Active Disease .....	62
	8.2.2 Probably Active Disease. ....	63
	8.2.3 Inactive Disease .....	63
8.3	Collection and Investigations of Urinary and Faecal Specimens .....	63
8.4	Results of Urine Investigations .....	64
8.5	Results of Faecal Investigations .....	64
8.6	Acute Anterior Uveitis and Faecal Cultures .....	65
8.7	Results of Faecal Cultures in Patients with Uveitis .....	66
8.8	Discussion .....	66
8.9	Pathological and Clinical Implications .....	67
	References .....	67

<b>9</b>	<b>Biochemical Parameters and <i>Klebsiella</i> in Ankylosing Spondylitis</b>	<b>69</b>
9.1	Introduction: The Use of Biochemical Parameters in Ankylosing Spondylitis	69
9.2	Selection of Ankylosing Spondylitis Patients and Controls	70
9.3	Assessment of Disease Activity	70
9.3.1	Active Disease	70
9.3.2	Probably Active Disease	71
9.3.3	Inactive Disease	71
9.4	Methods Used in These Studies	71
9.4.1	C-Reactive Protein Estimation	71
9.4.2	Erythrocyte Sedimentation Rate Measurement	71
9.4.3	Faecal Cultures	72
9.5	C-Reactive Protein and Disease Activity	72
9.6	Erythrocyte Sedimentation Rate and Disease Activity	73
9.7	Isolation of <i>Klebsiella</i> and Disease Activity	73
9.8	C-Reactive Protein and Erythrocyte Sedimentation Rate in Ankylosing Spondylitis Patients with and Without <i>Klebsiella</i>	74
9.9	Discussion	75
9.10	Pathological and Clinical Implications	77
	References	77
<b>10</b>	<b>Binding of <i>Klebsiella</i> Antisera to HLA-B27 Cells</b>	<b>79</b>
10.1	Introduction: The Problem of HLA-B27 in Ankylosing and Its Link to <i>Klebsiella</i>	79
10.2	Patients and Control Subjects	80
10.3	Rabbit Antisera	80
10.4	Specificity Tests on Antisera	81
10.5	Enzyme Immunoassay to Investigate the Binding of Anti- <i>Klebsiella</i> Sonicate Preparation to HLA-B27 Lymphocytes	82
10.6	Absorption Experiments	83
10.7	Results of Antisera Specificity	84
10.8	Results of Enzyme Immunoassay and Absorption Experiments	85
10.9	Pathological and Clinical Implications	86
	References	88
<b>11</b>	<b>IgA Antibodies to <i>Klebsiella</i> and Other Gram-Negative Bacteria in Ankylosing Spondylitis</b>	<b>91</b>
11.1	Introduction: The Problem of Elevated Serum IgA in Ankylosing Spondylitis and Its Link to <i>Klebsiella</i>	91
11.2	Selection of Serum Samples from Ankylosing Spondylitis Rheumatoid Arthritis, Psoriasis Patients and Healthy Controls	92
11.3	Enzyme-Linked Immunosorbent Assay (ELISA)	92
11.4	Absorption Studies	93
11.5	C-Reactive Protein Results	93

11.6	Total Serum IgA Values . . . . .	94
11.7	IgA Antibodies to <i>Klebsiella</i> . . . . .	94
11.8	Faecal Cultures and Anti- <i>Klebsiella</i> Antibodies . . . . .	97
11.9	Second Study Against the Gram-Negative Microorganisms: <i>Klebsiella</i> , <i>Salmonella</i> , <i>Yersinia</i> and <i>Pseudomonas</i> . . . . .	97
11.9.1	Serum C-Reactive Protein Level . . . . .	99
11.9.2	Serum IgA . . . . .	99
11.9.3	Serum IgG . . . . .	99
11.9.4	Serum IgM . . . . .	100
11.9.5	ELISA IgA Antibodies . . . . .	100
11.9.6	ELISA IgG Antibodies . . . . .	101
11.9.7	ELISA IgM Antibodies . . . . .	102
11.10	Pathological and Clinical Implications. . . . .	102
	References . . . . .	103
<b>12</b>	<b>IgA Antibodies to <i>Klebsiella</i> Measured by Immunoblotting . . . . .</b>	<b>105</b>
12.1	Introduction: The Problem of Elevated Serum IgA in Ankylosing Spondylitis and Its Link to <i>Klebsiella</i> . . . . .	105
12.2	Selection of Serum Samples from Ankylosing Spondylitis, Rheumatoid Arthritis Patients and Healthy Controls . . . . .	106
12.3	Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE). . . . .	106
12.3.1	Immunoblot Analysis . . . . .	107
12.4	Characteristics of the Four Study Groups. . . . .	107
12.5	Analysis of the Results of the Immunoblotting Assay . . . . .	108
12.6	Comparison of Serum and Synovial Fluids . . . . .	109
12.7	Pathological and Clinical Implications. . . . .	109
	References . . . . .	111
<b>13</b>	<b>Antibodies to <i>Klebsiella</i> in Ankylosing Spondylitis Measured by Bacterial Agglutination and ELISA Against Lipopolysaccharides . . . . .</b>	<b>113</b>
13.1	Introduction: Gram-Negative Bacteria in Ankylosing Spondylitis . .	113
13.2	First Study: Patients and Controls . . . . .	114
13.2.1	Sera from Ankylosing Spondylitis Patients . . . . .	114
13.2.2	Sera from Rheumatoid Arthritis Patients . . . . .	114
13.3	Statistical Analysis of Patient Groups and Controls. . . . .	114
13.4	Coombs Agglutination Assay . . . . .	115
13.5	Results of Coombs Agglutination Assay . . . . .	116
13.6	Second Study: Patients and Controls . . . . .	118
13.7	ELISA of Bacterial Lipopolysaccharide Samples . . . . .	118
13.8	Results of Study on Bacterial Lipopolysaccharides . . . . .	119
13.9	Clinical Implications and Discussion . . . . .	119
	References . . . . .	122

<b>14 Dutch and German Patients with Ankylosing Spondylitis Have Antibodies to <i>Klebsiella</i></b>	123
14.1 The Netherlands Connection: An Introduction	123
14.2 Amsterdam: Location and History	123
14.3 Patients and Controls	124
14.4 Serum C-Reactive Protein Levels	124
14.5 Indirect Immunofluorescence Studies with <i>Klebsiella</i> in Ankylosing Spondylitis and Acute Anterior Uveitis Patients and <i>Proteus</i> in Rheumatoid Patients from the Netherlands	125
14.5.1 IgA Antibodies to <i>Klebsiella pneumoniae</i>	126
14.5.2 IgG Antibodies to <i>Proteus mirabilis</i>	126
14.6 German Studies on <i>Klebsiella</i> in Ankylosing Spondylitis	126
14.6.1 Lübeck	127
14.6.2 Kiel	129
14.7 ELISA Studies on German Patients	129
14.8 Clinical Implications and Conclusions	130
14.9 Conclusions	131
References	131
<b>15 Spanish, Finnish and Swedish Patients with Ankylosing Spondylitis Have Antibodies to <i>Klebsiella</i></b>	133
15.1 The Spanish Connection: An Introduction	133
15.2 Barcelona: Location and History	133
15.3 Catalan Patients and Controls	134
15.4 Statistical Analysis	134
15.5 Results on Catalan Patients	135
15.6 Turku: The Finland Connection	136
15.7 Results of Finnish Patients	136
15.8 Uppsala and the Swedish Connection	137
15.9 Swedish Studies	138
15.10 General Discussion and Conclusions	139
References	139
<b>16 Molecular Mimicry Between <i>Klebsiella</i> Pullulanase Enzyme, HLA-B27 and Collagens I and IV</b>	141
16.1 Introduction: The Association of HLA-B27 with Ankylosing Spondylitis Is the Central Research Issue in This Disease	141
16.2 Computer Search for Other <i>Klebsiella</i> Proteins Cross-Reacting with HLA-B27	142
16.3 Peptide ELISA Studies in Ankylosing Spondylitis Patients	143
16.3.1 B*2705 Results	144
16.3.2 pulD Peptide Results	145
16.3.3 Scrambled Control Peptide Results	146
16.4 Pullulan and Pullulanase	147

16.5	ELISA Studies on Effect of Antibody in Bacteria Grown in Presence or Absence of Pullulan . . . . .	148
16.5.1	Results of ELISA Studies in Ankylosing Spondylitis Patients . . . . .	149
16.5.2	Results of ELISA Studies in Rheumatoid Arthritis Patients . . . . .	149
16.6	Serum Antibodies to the Pullulanase (pulA) Enzyme . . . . .	149
16.7	ELISA Studies on Collagen Types I and IV . . . . .	151
16.8	Discussion and Conclusions . . . . .	153
	References . . . . .	157
<b>17</b>	<b>Antibodies to <i>Klebsiella</i> and HLA-B27 Peptides in Ankylosing Spondylitis Patients from Southern Japan . . . . .</b>	<b>159</b>
17.1	The Japanese Connection: An Introduction . . . . .	159
17.2	Otsu: Location and History . . . . .	160
17.3	Patients and Controls . . . . .	160
17.4	Results of ELISA Studies on Bacteria . . . . .	161
17.5	Results of ELISA Studies on HLA-B27 and Pullulanase Peptide Sequences . . . . .	163
17.5.1	Antibodies to the HLA-B27 Sequence . . . . .	164
17.5.2	Antibodies to the Pullulanase-D Peptide . . . . .	165
17.5.3	Antibodies to Scrambled pulD Control Peptide . . . . .	167
17.6	Discussion and Conclusions . . . . .	167
	References . . . . .	169
<b>18</b>	<b>Ankylosing Spondylitis Sera Are Cytotoxic to Cells Bearing HLA-B27 Sequences . . . . .</b>	<b>171</b>
18.1	Introduction: The Association of HLA-B27 with the <i>Klebsiella</i> Nitrogenase and <i>Klebsiella</i> Pullulanase Enzymes . . . . .	171
18.2	Antibodies to <i>Klebsiella</i> Nitrogenase Reductase in Patients with Ankylosing Spondylitis . . . . .	172
18.3	Sera from Ankylosing Spondylitis and Rheumatoid Arthritis Patients . . . . .	173
18.4	Synthetic Peptides and ELISA . . . . .	174
18.5	Antibodies to Peptide Antigens in Ankylosing Spondylitis Patients . . . . .	175
18.5.1	Antibodies to the HLA-B27 Peptide . . . . .	175
18.5.2	Antibodies to the <i>Klebsiella pneumoniae</i> Nitrogenase Peptide . . . . .	175
18.5.3	Antibodies to the <i>Klebsiella pneumoniae</i> Pullulanase Peptide . . . . .	175
18.6	Antibodies to Peptide Antigens in Rheumatoid Arthritis Patients . . . . .	176
18.6.1	HLA-DRB1*0404 Peptide . . . . .	176

18.6.2	<i>Proteus mirabilis</i> Haemolysin Peptide . . . . .	176
18.6.3	Type XI Collagen Peptide. . . . .	176
18.7	Preparation of Sheep Red Blood Cells for Cytotoxicity Assay . . . . .	177
18.8	Cytotoxicity Studies in Ankylosing Spondylitis Patients. . . . .	178
18.9	Cytotoxicity Studies in Rheumatoid Arthritis Patients. . . . .	179
18.9.1	EQRRAA Peptide. . . . .	179
18.9.2	LRREI Peptide . . . . .	180
18.9.3	EDERAA Peptide. . . . .	181
18.10	Discussion and Conclusions. . . . .	181
	References . . . . .	184
<b>19</b>	<b>Pathogenesis of Ankylosing Spondylitis and <i>Klebsiella</i> Substrates. . . . .</b>	<b>187</b>
19.1	Introduction: The Association of Serum IgA in Ankylosing Spondylitis Points to a Bowel Microbe . . . . .	187
19.2	Marseille: Location and History. . . . .	190
19.3	Lymphangiographic Studies . . . . .	190
19.4	The Proposed Model for the Pathogenesis of Ankylosing Spondylitis . . . . .	191
19.5	Importance for Early Diagnosis of Ankylosing Spondylitis . . . . .	194
19.6	The Concept of 'Gram-Negative Reactive Arthritis' and HLA-B27. . . . .	194
19.6.1	Paronen's Study . . . . .	194
19.6.2	The 'USS Little Rock' Epidemic . . . . .	195
19.6.3	<i>Salmonella</i> Reactive Arthritis in Finland . . . . .	195
19.6.4	<i>Yersinia</i> Reactive Arthritis . . . . .	195
19.7	Starch as the Source of the Main Bacterial Substrate in the Gut . . . . .	196
19.7.1	A Patient Provides an Important Clue . . . . .	196
19.7.2	Fecal Flora in Vegetarian Seventh Day Adventists . . . . .	196
19.7.3	Carbohydrates as Bacterial Substrates . . . . .	197
19.7.4	Ileostomy Studies . . . . .	197
19.7.5	Oral Hydrogen Excretion Studies. . . . .	197
19.8	Composition of the 'Low Starch Diet' . . . . .	200
19.9	Discussion and Conclusions. . . . .	200
	References . . . . .	202
<b>20</b>	<b>Ankylosing Spondylitis and the 'Low-Starch Diet' . . . . .</b>	<b>203</b>
20.1	Introduction: The Therapeutic Imperative . . . . .	203
20.2	Current Therapeutic Interventions . . . . .	203
20.2.1	Physiotherapy and Exercise . . . . .	203
20.2.2	Sulphasalazine . . . . .	204
20.2.3	Sulphasalazine and <i>Klebsiella</i> . . . . .	204
20.2.4	Moxifloxacin in Ankylosing Spondylitis . . . . .	204



20.3	'Low-Starch Diet' in Controls . . . . .	205
20.3.1	Open Study with 21 Healthy Controls . . . . .	205
20.3.2	Nutritionally Controlled Study with 11 Healthy Subjects . . . . .	205
20.4	The 'Low-Starch Diet' in Ankylosing Spondylitis Patients . . . . .	207
20.4.1	How Not to Do 'Coded Runs' Involving Diet Modification . . . . .	207
20.4.2	Ankylosing Spondylitis Patients Partaking in the Diet Study . . . . .	209
20.4.3	Erythrocyte Sedimentation Rate and Haemoglobin Correlation . . . . .	209
20.4.4	C-Reactive Protein and Haemoglobin Correlation . . . . .	209
20.5	'Low-Starch Diet' and Levels of Inflammation in Ankylosing Spondylitis Patients on the Diet . . . . .	211
20.6	Discussion and Conclusions . . . . .	211
20.7	A Patient Followed for 28 years. (Mrs. Beard's Story) . . . . .	215
20.8	A Sceptic Tries the 'Low-Starch Diet' (George's Story) . . . . .	217
20.9	Carol Sinclair and Her Book <i>The IBS Low-Starch Diet</i> . . . . .	218
	References . . . . .	219
<b>21</b>	<b>The Problem of Crohn's Disease and <i>Klebsiella</i></b> . . . . .	<b>221</b>
21.1	Introduction: Crohn's Disease . . . . .	221
21.2	Ghent: Location and History . . . . .	221
21.3	The Link Between Ankylosing Spondylitis and Crohn's Disease . . . . .	222
21.4	Birmingham: Location and History . . . . .	222
21.5	Antibodies to <i>Yersinia</i> and <i>Klebsiella</i> but Not <i>Pseudomonas</i> in Crohn's Disease Patients . . . . .	223
21.6	IBD Patients from the Royal Free Hospital in London Have Antibodies to <i>Klebsiella</i> . . . . .	223
21.7	Coeliac Disease Patients from St. Thomas' Hospital Do Not Have Antibodies Against <i>Klebsiella</i> . . . . .	224
21.8	Antibodies to <i>Klebsiella</i> in Crohn's Disease and in Ankylosing Spondylitis Patients from Scotland . . . . .	229
21.8.1	Glasgow . . . . .	230
21.8.2	Edinburgh . . . . .	230
21.9	Immune Response to Collagens in Patients with Crohn's Disease and Ankylosing Spondylitis . . . . .	231
21.10	Conclusion: Crohn's Disease Is Caused by <i>Klebsiella</i> in HLA-B27 Negative Individuals . . . . .	233
	References . . . . .	234
<b>22</b>	<b>Ankylosing Spondylitis and 'Popper Sequences'</b> . . . . .	<b>235</b>
22.1	Introduction to 'Popper Sequences' . . . . .	235
22.2	Components of a 'Popper Sequence' . . . . .	236

22.3	First Popper Sequence . . . . .	236
22.4	Second Popper Sequence . . . . .	237
22.5	Third Popper Sequence. . . . .	238
22.6	Fourth Popper Sequence. . . . .	239
22.7	Fifth Popper Sequence . . . . .	240
22.8	Sixth Popper Sequence . . . . .	241
22.9	Seventh Popper Sequence. . . . .	242
22.10	Eighth Popper Sequence. . . . .	243
22.11	Ninth Popper Sequence . . . . .	244
22.12	Tenth Popper Sequence . . . . .	245
22.13	Eleventh Popper Sequence . . . . .	246
22.14	Twelfth Popper Sequence . . . . .	247
22.15	Thirteenth Popper Sequence. . . . .	248
22.16	Therapeutic Implications . . . . .	249
	References . . . . .	249
	<b>Index.</b> . . . . .	<b>251</b>

Ankylosing spondylitis and Klebsiella

Ebringer, A.

2013, XX, 256 p., Hardcover

ISBN: 978-1-4471-4299-7